Cellicon Valley companies closed out 2022 with a roar. Madrigal Pharmaceuticals announced a breakthrough in NASH that could result in the first-approved drug for that disease. Galera Therapeutics closed out December with plans to seek approval for its severe oral mucositis therapy.
Greater Philadelphia Q4 2022 News Recap – December was a Pivotal Month for Cellicon Valley Companies
Published on :